Nasuh Buyukkaramikli
Overview
Explore the profile of Nasuh Buyukkaramikli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
241
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Freedland S, Fernandes L, De Solda F, Buyukkaramikli N, Mundle S, McCarthy S, et al.
Target Oncol
. 2024 Nov;
20(1):139-148.
PMID: 39522076
Background: Patients with high-risk localized and locally advanced prostate cancer (HR-LPC/LAPC) have increased risk of metastasis, leading to reduced survival rates. Segmenting the disease course [time to recurrence, recurrence to...
2.
Palmer S, Lin Y, Martin T, Jagannath S, Jakubowiak A, Usmani S, et al.
Oncol Ther
. 2023 Jun;
11(3):313-326.
PMID: 37270762
Introduction: Extrapolating long-term overall survival (OS) from shorter-term clinical trial data is key to health technology assessment in oncology. However, extrapolation using conventional methods is often subject to uncertainty. Using...
3.
Richards F, Kodjamanova P, Chen X, Li N, Atanasov P, Bennetts L, et al.
Clinicoecon Outcomes Res
. 2022 May;
14:293-307.
PMID: 35509962
Objective: To review and qualitatively synthesize the evidence related to the economic burden of COVID-19, including healthcare resource utilization and costs. Methods: A systematic review of studies that assessed the...
4.
Bovenberg J, Penton H, Buyukkaramikli N
Value Health
. 2021 May;
24(5):691-698.
PMID: 33933238
Objectives: In January 2009, the National Institute for Health and Care Excellence introduced supplementary guidance for end-of-life (EoL) treatments, which allowed treatments with an incremental cost-effectiveness ratio over the regular...
5.
Cacciatore P, Visser L, Buyukkaramikli N, van der Ploeg C, Elske van den Akker-van Marle M
Int J Neonatal Screen
. 2020 Nov;
6(4).
PMID: 33238605
Introduction: Cost-effectiveness (CEA) and cost-utility analyses (CUA) have become popular types of economic evaluations (EE) used for evidence-based decision-making in healthcare resource allocation. Newborn screening programs (NBS) can have significant...
6.
Armstrong N, Buyukkaramikli N, Penton H, Riemsma R, Wetzelaer P, Carrera V, et al.
Health Technol Assess
. 2020 Oct;
24(51):1-220.
PMID: 33108266
Background: There have been no licensed treatment options in the UK for treating thrombocytopenia in people with chronic liver disease requiring surgery. Established management largely involves platelet transfusion prior to...
7.
Grustam A, Buyukkaramikli N, Koymans R, Vrijhoef H, Severens J
PLoS One
. 2019 Jun;
14(6):e0218083.
PMID: 31220101
Objectives: Value of information (VOI) analysis provides information on opportunity cost of a decision in healthcare by estimating the cost of reducing parametric uncertainty and quantifying the value of generating...
8.
Crown W, Buyukkaramikli N, Sir M, Thokala P, Morton A, Marshall D, et al.
Value Health
. 2018 Sep;
21(9):1019-1028.
PMID: 30224103
Background: Constrained optimization methods are already widely used in health care to solve problems that represent traditional applications of operations research methods, such as choosing the optimal location for new...
9.
Grustam A, Severens J, De Massari D, Buyukkaramikli N, Koymans R, Vrijhoef H
Value Health
. 2018 Jul;
21(7):772-782.
PMID: 30005749
Objectives: To assess the cost effectiveness of home telemonitoring (HTM) and nurse telephone support (NTS) compared with usual care (UC) in the management of patients with chronic heart failure, from...
10.
Dickson R, Boland A, Duarte R, Kotas E, Woolacott N, Hodgson R, et al.
Appl Health Econ Health Policy
. 2018 May;
16(4):429-432.
PMID: 29808296
No abstract available.